financetom
Business
financetom
/
Business
/
Ugro Capital expects disbursements worth ₹9,000-10,000 crore in FY24
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ugro Capital expects disbursements worth ₹9,000-10,000 crore in FY24
Nov 1, 2023 3:41 AM

Shachindra Nath, Vice Chairman and Managing Director of Ugro Capital, a small business lending fintech platform, anticipates disbursements in the range of ₹9,000-10,000 crore for the upcoming financial year.

Share Market Live

NSE

“This year-end, we should be around ₹9,000-10,000 crore and that is a function of our ₹550 crore of average disbursement per month of which 50% is an off-balance sheet and 50% is on the balance sheet.”

Nath expects the net interest margin (NIM) to remain steady and credit costs to be around 2%.

The company's restructured book is marginal and no additional stress is anticipated to arise from this segment.

Also Read

| Shriram Finance’s Umesh Revankar on NBFC journey and more — full text of his interview

Earlier this month, the company announced a 73% year-on-year (YoY) rise in assets under management (AUM) to ₹7,590 crore.

According to a business update for the second quarter filed with the exchange on October 10, the non-banking financial company (NBFC) reported a 52% YoY increase in gross loan origination, amounting to ₹2,500 crore. Net loan origination was 34% higher YoY at ₹1,470 crore.

Also Read | These are Prabhudas Lilladher's top picks among NBFCs

Back in August, Nath shared with CNBC-TV18 that approximately 30% of their loans are categorised as unsecured, while the remaining 70% are classified as secured, underscoring the diverse nature of their loan portfolio.

For more details, watch the accompanying video

(Edited by : Shweta Mungre)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PRESS DIGEST- Wall Street Journal - Dec 9
PRESS DIGEST- Wall Street Journal - Dec 9
Dec 9, 2024
Dec 9 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Omnicom Group ( OMC ) is in advanced talks to acquire Interpublic Group in an all-stock deal, which is likely to value Interpublic at between $13 billion and $14 billion. -...
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals
Dec 9, 2024
04:38 AM EST, 12/09/2024 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals. In the study, mitapivat demonstrated a statistically significant reduction in transfusion burden compared with placebo, the company said. The company...
Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment
Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment
Dec 9, 2024
04:43 AM EST, 12/09/2024 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Engraftment is the process under which transplanted stem cells enter the bloodstream,...
Merck's Study Shows Complete Response Rate of 100% for Zilovertamab Vedotin With R-CHP in Cancer Patients
Merck's Study Shows Complete Response Rate of 100% for Zilovertamab Vedotin With R-CHP in Cancer Patients
Dec 9, 2024
04:54 AM EST, 12/09/2024 (MT Newswires) -- Merck & Co. ( MRK ) said Sunday that its phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, its investigational antibody-drug conjugate in combination with R-CHP for the treatment of patients with previously untreated diffuse large B-cell lymphoma, achieved a 100% complete response rate. Patients were treated with the drug at 1.75 mg/kg, which...
Copyright 2023-2026 - www.financetom.com All Rights Reserved